Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novo Nordisk has cut 9,000 jobs worldwide and reduced its 2025 profit growth guidance. The new CEO is fulfilling a cost reallocation promise, leading to a decrease in operating profit growth projection from 10% to 16% down to 4% to 10%. The company's restructuring efforts are aimed at increasing efficiency and reducing costs. In other news, the ousted CDC director Susan Monarez will testify in front of the Senate, and a recent report from the Maha commission emphasizes chronic diseases and potential vaccine reform.Biotechs are using contingent value rights (CVRs) to close the gap between buyer and seller expectations in transactions amid a down market. Novartis is actively pursuing acquisitions, particularly in the cardiovascular space, while Novo Nordisk is restructuring and cutting costs, impacting profit growth projections. Amgen is looking beyond the scrutiny of one obesity asset to focus on a fuller portfolio. Trilink Biotechnologies offers process development services for nucleic acid therapeutic development. In other news, LB Neuroscience files for a $228 million IPO, Novartis acquires Tourmaline for $1.4 billion, and Hengrui licenses a heart disease drug to a US startup for up to $1 billion. The FDA debuts a consumer 'green list' instead of addressing the GLP-1 compounding fight. Thank you for tuning in to Pharma and Biotech daily.

Support the show